Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 11

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 11
---
.

We are registering for resale an aggregate of 1,565,044,860 shares of common stock, including an aggregate of 1,542,317,700 shares of common stock issuable upon exercise of the Warrants, and the issuance and sale of these shares (or the perception that such sales may occur) may depress the market price of our common stock and cause immediate and substantial dilution to our existing stockholders.

As of March 21, 2025, we had 16,999,626 shares of common stock issued and outstanding. We are registering for resale an aggregate of
1,565,044,860 shares of our common stock, which represents approximately 9,206% of the 16,999,626 shares of our common stock outstanding and approximately 99% of our total shares of common stock outstanding assuming the exercise of all of the
Warrants and issuance of the maximum number of shares of common stock that may be issuable upon exercise of the Warrants. The Series B Common Stock Warrants are subject to a zero exercise price provision, pursuant to which the Series B Common Stock
Warrants can be exercised without further payment to us and for three times the number of shares of common stock issuable upon exercise of the Series B Common Stock Warrants for cash. The Common Warrants include a reset provision described below
under “Private Placement,” pursuant to which the exercise price of the Common Warrants may be reduced to a price not lower than $0.132 (the “Floor Price”). On April 21, 2025, the closing sale price of our common stock was $0.641
per share.

If the exercise price of the Series A Common Stock Warrants is reduced to the Floor Price pursuant to the reset provision, the 28,042,138
outstanding Series A Common Stock Warrants would become exercisable for an aggregate of up to 280,421,380 shares of common stock. The 28,042,138 outstanding Series B Common Stock Warrants would be exercisable for an aggregate of up to
84,126,414 shares of common stock assuming the Series B Common Stock Warrants are exercised pursuant to the zero exercise price provision. In the event that the exercise price of the Series B Common Stock Warrants is reduced to the Floor Price
pursuant to the reset provision, the Series B Common Stock Warrants would become exercisable for an aggregate of up to 420,632,070 shares of common stock, or an aggregate of up